Novo Nordisk will be happy with the results after Pfizer has dropped two SCD assets in recent years. Credit: JHVEPhoto / Shutterstock.com A Phase III trial of Novo Nordisk’s once-daily tablet has met ...
Trump's executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.
Agenus has reported results from a Phase II trial, evaluating the combination of BOT, BAL, and agenT-797 alongside ramucirumab and paclitaxel, in advanced PD-1 refractory gastroesophageal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results